Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
investorenquiries@pharmaust.com+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

Daily Archives: 10/05/2023

Independent tests show MPL retains long-term shelf-life

News and Announcements 2023By PharmAust10/05/2023

12-month GMP Stability (final)

MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

Twitter
YouTube

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
8 Oct

💰 PharmAust (ASX: PAA) secures an $887K rebate under Australia’s R&D Tax Incentive, boosting resources for our ALS research and monepantel development! Further rebate expected soon to support our Phase 2/3 trials. #Biotech #ALSResearch #PharmAust

Reply on Twitter 1843778269679890469 Retweet on Twitter 1843778269679890469 2 Like on Twitter 1843778269679890469 6 Twitter 1843778269679890469
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
17 Sep

PharmAust has submitted a request for orphan medicinal product designation to the European Medicines Agency for its lead drug monepantel for the treatment of amyotrophic lateral sclerosis (ALS). @PharmAust #ASX $PAA

Reply on Twitter 1836188877763084695 Retweet on Twitter 1836188877763084695 1 Like on Twitter 1836188877763084695 7 Twitter 1836188877763084695
pharmaust PharmAust @pharmaust ·
17 Sep

📎PharmAust submits Orphan Medicinal Product Designation request to EMA for monepantel, targeting ALS! If granted, this would provide regulatory support & 10 years of EU market exclusivity. Decision expected in Dec 2024. Exciting times ahead! 🌍 #PharmAust #Biotech #ALS

Reply on Twitter 1835861750488711336 Retweet on Twitter 1835861750488711336 1 Like on Twitter 1835861750488711336 7 Twitter 1835861750488711336
Load More

Copyright © 2024 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top